Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
| Revenue (Most Recent Fiscal Year) | $3.11M |
| Net Income (Most Recent Fiscal Year) | $-24.13M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.79 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -675.52% |
| Return on Assets (Trailing 12 Months) | -175.68% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.27 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $65.21 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-8.40 |
| Earnings per Share (Most Recent Fiscal Year) | $-1747.60 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 3.29M |
| Free Float | 3.29M |
| Market Capitalization | $5.26M |
| Average Volume (Last 20 Days) | 13.04M |
| Beta (Past 60 Months) | 5.77 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.01% |
| Percentage Held By Institutions (Latest 13F Reports) | 8.06% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |